Ubs Group Ag Transcode Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
BUY
$0.33 - $984.0 $382 - $1.14 Million
1,159 New
1,159 $0
Q2 2022

Aug 10, 2022
SELL
$1.2 - $3.03 $4,767 - $12,038
-3,973 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$2.03 - $3.01 $2,600 - $3,855
-1,281 Reduced 24.38%
3,973 $11,000
Q4 2021

Feb 14, 2022
SELL
$2.42 - $3.41 $200 - $283
-83 Reduced 1.56%
5,254 $13,000
Q3 2021

Nov 15, 2021
BUY
$2.37 - $6.45 $12,648 - $34,423
5,337 New
5,337 $16,000

Others Institutions Holding RNAZ

# of Institutions
1
Shares Held
6.5K
Call Options Held
0
Put Options Held
0
View Full List

About Transcode Therapeutics, Inc.

RNAZ Quotes by TradingView
  • Ticker RNAZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,977,200
  • Market Cap $4.93M
  • Description
  • TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...
More about RNAZ
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email